publication . Article . 2021

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial

Waly Dioh; M. Chabane; C Tourette; A Azbekyan; C Morelot-Panzini; L A Hajjar; M Lins; G B Nair; T Whitehouse; J Mariani; ...
Open Access English
  • Published: 01 Dec 2021 Journal: Trials, volume 22 (eissn: 1745-6215, Copyright policy)
  • Publisher: BioMed Central
  • Country: France
Abstract
<jats:title>Abstract</jats:title><jats:sec> <jats:title>Objectives</jats:title> <jats:p>As of December, 1<jats:sup>st</jats:sup>, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly population at risk, Biophyt...
Persistent Identifiers
Subjects
free text keywords: Letter, COVID-19, SARS-CoV2, randomised controlled trial, Renin Angiotensin System, Mas receptor, angiotensin converting enzyme-2, 20-hydroxyecdysone, BIO101, Inflammation, Acute respiratory Distress Syndrome, [SDV]Life Sciences [q-bio], Pharmacology (medical), Medicine (miscellaneous), lcsh:Medicine (General), lcsh:R5-920, Randomized controlled trial, law.invention, law, 2019-20 coronavirus outbreak, In patient, Coronavirus disease 2019 (COVID-19), Medicine, business.industry, business, Pharmacotherapy, Mas receptor, Disease progression, Respiratory system, Emergency medicine, medicine.medical_specialty
Related Organizations
Communities
COVID-19
Download fromView all 6 versions
Trials
Article
Provider: UnpayWall
Trials
Article . 2021
Provider: Crossref
Trials
Article . 2021

Author details 1Biophytis SA, Sorbonne Université - BC9, 4 place Jussieu, 75005 Paris, France. 2Biophytis, Inc, 210 Broadway, Suite #201, Cambridge, MA 02139, USA. 3Service de Pneumologie, Médecine Intensive et Réanimation - R3S (SPMIR-R3S), Hôpital Pitié-Salpêtrière - APHP, Paris, France. 4Universidade de São Paulo Instituto do Coração, São Paulo, SP, Brasil. 5General Hospital Sint-Maarten, Mechelen, Belgium. 6Oakland University William Beaumont School of Medicine, Royal Oak, MI, USA. 7Queen Elizabeth Hospital Birmingham, Birmingham B15 2GW, UK. 8Sorbonne Université, CNRS - Institut de Biologie Paris Seine (B2A), 75005 Paris, France. 9Sorbonne Université, CNRS - Institut de Biologie Paris Seine (BIOSIPE), 75005 Paris, France.

Any information missing or wrong?Report an Issue